CAMP4 Therapeutics Corporation (NASDAQ: CAMP) announced preclinical data showing its experimental drug CMP-002 improved seizure threshold and severity in a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE